MPN Hub

During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the MPN Hub was pleased to speak with Claire Harrison, Guy’s and St Thomas’ NHS Foundation Trust, London, UK. We asked, What are the latest findings from the phase I/II study of nuvisertib in combination with momelotinib in patients with relapsed/refractory myelofibrosis (R/R MF)?In this interview, Harrison discusses key findings from Arm 3 of the trial (NCT04176198), which enrolled patients who had been previously treated with a Janus kinase inhibitor (JAKi) other than momelotinib. The study aimed to identify the recommended phase II dose (RP2D) of nuvisertib when administered in combination with momelotinib, and to assess the safety, clinical activity (spleen volume reduction [SVR] and total symptom score [TSS] improvement), and pharmacokinetics and pharmacodynamic markers (including cytokines and bone marrow fibrosis).This educational resource is independently supported by Sumitomo. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the MPN Hub was pleased to speak with Jean-Jacques Kiladjian, Université Paris Cité, Paris, FR. We asked, What are the key findings from the 12-month primary endpoint analysis of the ROP-ET phase III study? In this interview, Kiladjian first provided an overview of the phase III ROP-ET (NCT06514807) study design and key patient eligibility criteria. He then discussed the primary endpoint results, highlighting that the ROP-ET study met the primary endpoint – a composite durable hematologic and clinical response after 12 months. Finally, Kiladjian explored the safety profile of ropeginterferon alfa-2b observed in the study.This educational resource is independently supported by AOP Health. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource. 

The MPN Hub was pleased to speak with Jennifer Vaughn, The Ohio State University Comprehensive Cancer Center, Columbus, US. We asked, How might extended-release formulations of ruxolitinib benefit patients with MF? In this interview, Vaughn discusses the potential benefits of an extended-release ruxolitinib formulation for patients with myelofibrosis, noting that ruxolitinib’s short half-life necessitates twice-daily dosing, which may reduce adherence. Vaughn highlights that an extended-release formulation, enabling once-daily dosing, may improve adherence, maintain disease control, and lessen cytopenias. This educational resource is independently supported by Incyte. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

The MPN Hub was pleased to speak with Jean-Jacques Kiladjian, Université de Paris and Hôpital Saint-Louis, Paris, FR. We asked, What are the unmet needs in the management of myelofibrosis-related anemia? In this interview, Kiladjian explores the impact and multifactorial causes of myelofibrosis-related anemia, with particular attention to the on-target effects of JAK inhibition. He reviews currently approved JAK inhibitors, emphasizing the anemia benefits seen with momelotinib and pacritinib. Kiladjian also underscores that JAK inhibitors alone do not completely address myelofibrosis-related anemia, highlighting the potential of JAK inhibitor-based combination therapies to address this unmet need.

The MPN Hub spoke with Aaron Gerds, Cleveland Clinic Taussig Cancer Institute, Cleveland, US. We asked about the treatment of patients with myelofibrosis-associated anemia.During this interview, Gerds discussed the burden and management of myelofibrosis-associated anemia. He explained its prevalence, prognostic importance, and multifactorial causes. Gerds also reviewed currently available therapies, combination strategies, and the need for further disease-modifying approaches.This educational resource is independently supported by GSK. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

During the MPN Hub Steering Committee meeting, Francesco Passamonti, Università degli Studi di Milano, Milan, IT, chaired a discussion on novel targeted therapies for relapsed/refractory (R/R) myelofibrosis (MF), with a focus on PIM1 kinase inhibition. This discussion also featured Tiziano Barbui, Haifa Kathrin Al-Ali, Steffen Koschmieder, Jean-Jacques Kiladjian, Aaron Gerds, and Laura Michaelis.  Passamonti provides an overview of the mechanism of action of PIM1 kinase inhibitors. He then discusses results from a phase I/II trial of nuvisertib, a first-in-class selective PIM1 kinase inhibitor, in patients with R/R MF.   This educational resource is independently supported by Sumitomo Pharma. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.   

During the MPN Hub Steering Committee meeting featuring John Mascarenhas, Steffen Koschmieder, Laura Michaelis, and Tiziano Barbui, Ruben Mesa discussed the use of momelotinib and luspatercept for the treatment of patients with myelofibrosis and anemia.This educational resource is independently supported by GSK and Bristol Myers Squibb. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource. 

This educational resource is independently supported by GSK. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.During the European School of Haematology (ESH) 4th How to Diagnose and Treat: CML/MPN conference, the MPN Hub hosted a symposium titled “Anemia in myelofibrosis: Sequencing therapies to optimize patient outcomes.”The symposium closed with a panel Q&A session with live audience participation. The panelists, Jean-Jacques Kiladjian, Francesco Passamonti, and Paola Guglielmelli, shared their perspectives on the optimal sequencing of therapies for patients with myelofibrosis-related anemia, the use of iron chelation therapy, potential future combination therapies, and the use of anemia supportive agents.